470 related articles for article (PubMed ID: 11738764)
1. Enhanced CD8+ T cell immune response against a V3 loop multi-epitope polypeptide (TAB13) of HIV-1 Env after priming with purified fusion protein and booster with modified vaccinia virus Ankara (MVA-TAB) recombinant: a comparison of humoral and cellular immune responses with the vaccinia virus Western Reserve (WR) vector.
Gómez CE; Rodríguez D; Rodríguez JR; Abaitua F; Duarte C; Esteban M
Vaccine; 2001 Dec; 20(5-6):961-71. PubMed ID: 11738764
[TBL] [Abstract][Full Text] [Related]
2. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
Gómez CE; Abaitua F; Rodríguez D; Esteban M
Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
[TBL] [Abstract][Full Text] [Related]
3. Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes.
Gherardi MM; Nájera JL; Pérez-Jiménez E; Guerra S; García-Sastre A; Esteban M
J Virol; 2003 Jun; 77(12):7048-57. PubMed ID: 12768024
[TBL] [Abstract][Full Text] [Related]
4. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
[TBL] [Abstract][Full Text] [Related]
5. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
J Virol; 2017 May; 91(9):. PubMed ID: 28179536
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of HIV-1 Env-Specific CD8 T Cell Responses Using Interferon-Stimulated Gene 15 as an Immune Adjuvant.
Gómez CE; Perdiguero B; Falqui M; Marín MQ; Bécares M; Sorzano CÓS; García-Arriaza J; Esteban M; Guerra S
J Virol; 2020 Dec; 95(2):. PubMed ID: 33115866
[TBL] [Abstract][Full Text] [Related]
7. Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule.
Gherardi MM; Pérez-Jiménez E; Nájera JL; Esteban M
J Immunol; 2004 May; 172(10):6209-20. PubMed ID: 15128809
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.
Shen X; Basu R; Sawant S; Beaumont D; Kwa SF; LaBranche C; Seaton KE; Yates NL; Montefiori DC; Ferrari G; Wyatt LS; Moss B; Alam SM; Haynes BF; Tomaras GD; Robinson HL
J Virol; 2017 Dec; 91(24):. PubMed ID: 29021394
[TBL] [Abstract][Full Text] [Related]
9. Brucella abortus conjugated with a peptide derived from the V3 loop of human immunodeficiency virus (HIV) type 1 induces HIV-specific cytotoxic T-cell responses in normal and in CD4+ cell-depleted BALB/c mice.
Lapham C; Golding B; Inman J; Blackburn R; Manischewitz J; Highet P; Golding H
J Virol; 1996 May; 70(5):3084-92. PubMed ID: 8627787
[TBL] [Abstract][Full Text] [Related]
10. Gender differences in human immunodeficiency virus type 1-specific CD8 responses in the reproductive tract and colon following nasal peptide priming and modified vaccinia virus Ankara boosting.
Peacock JW; Nordone SK; Jackson SS; Liao HX; Letvin NL; Yafal AG; Gritz L; Mazzara GP; Haynes BF; Staats HF
J Virol; 2004 Dec; 78(23):13163-72. PubMed ID: 15542668
[TBL] [Abstract][Full Text] [Related]
11. Co-expressing GP5 and M proteins under different promoters in recombinant modified vaccinia virus ankara (rMVA)-based vaccine vector enhanced the humoral and cellular immune responses of porcine reproductive and respiratory syndrome virus (PRRSV).
Zheng Q; Chen D; Li P; Bi Z; Cao R; Zhou B; Chen P
Virus Genes; 2007 Dec; 35(3):585-95. PubMed ID: 17922181
[TBL] [Abstract][Full Text] [Related]
12. A human immunodeficiency virus type 1 Env-granulocyte-macrophage colony-stimulating factor fusion protein enhances the cellular immune response to Env in a vaccinia virus-based vaccine.
Rodr Guez D; Rodr Guez JR; Llorente M; V Zquez I; Lucas P; Esteban M; Mart Nez-A C; Del Real G
J Gen Virol; 1999 Jan; 80 ( Pt 1)():217-223. PubMed ID: 9934705
[TBL] [Abstract][Full Text] [Related]
13. The Envelope-Based Fusion Antigen GP120C14K Forming Hexamer-Like Structures Triggers T Cell and Neutralizing Antibody Responses Against HIV-1.
Raman SC; Mejías-Pérez E; Gomez CE; García-Arriaza J; Perdiguero B; Vijayan A; Pérez-Ruiz M; Cuervo A; Santiago C; Sorzano COS; Sánchez-Corzo C; Moog C; Burger JA; Schorcht A; Sanders RW; Carrascosa JL; Esteban M
Front Immunol; 2019; 10():2793. PubMed ID: 31867001
[TBL] [Abstract][Full Text] [Related]
14. Improved humoral and cellular immune responses against the gp120 V3 loop of HIV-1 following genetic immunization with a chimeric DNA vaccine encoding the V3 inserted into the hepatitis B surface antigen.
Fomsgaard A; Nielsen HV; Bryder K; Nielsen C; Machuca R; Bruun L; Hansen J; Buus S
Scand J Immunol; 1998 Apr; 47(4):289-95. PubMed ID: 9600309
[TBL] [Abstract][Full Text] [Related]
15. Heterologous prime-boost-boost immunisation of Chinese cynomolgus macaques using DNA and recombinant poxvirus vectors expressing HIV-1 virus-like particles.
Bridge SH; Sharpe SA; Dennis MJ; Dowall SD; Getty B; Anson DS; Skinner MA; Stewart JP; Blanchard TJ
Virol J; 2011 Sep; 8():429. PubMed ID: 21899739
[TBL] [Abstract][Full Text] [Related]
16. Enhanced CD8+ T cell response to HIV-1 env by combined immunization with influenza and vaccinia virus recombinants.
Gonzalo RM; Rodríguez D; García-Sastre A; Rodríguez JR; Palese P; Esteban M
Vaccine; 1999 Feb; 17(7-8):887-92. PubMed ID: 10067695
[TBL] [Abstract][Full Text] [Related]
17. A Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV Immunogen.
Vijayan A; García-Arriaza J; Raman SC; Conesa JJ; Chichón FJ; Santiago C; Sorzano CÓ; Carrascosa JL; Esteban M
PLoS One; 2015; 10(7):e0133595. PubMed ID: 26208356
[TBL] [Abstract][Full Text] [Related]
18. Modified Vaccinia Virus Ankara Can Induce Optimal CD8
Wong YC; Croft S; Smith SA; Lin LCW; Cukalac T; La Gruta NL; Drexler I; Tscharke DC
J Virol; 2019 Nov; 93(21):. PubMed ID: 31375596
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of recombinant Modified Vaccinia Ankara Viruses (rMVA) expressing HIV-1 Indian subtype C gag-protease and env-gp120 genes in mice.
Kumar S; Seth P
Viral Immunol; 2004; 17(4):574-9. PubMed ID: 15671754
[TBL] [Abstract][Full Text] [Related]
20. A multigene HIV type 1 subtype C modified vaccinia Ankara (MVA) vaccine efficiently boosts immune responses to a DNA vaccine in mice.
Shephard E; Burgers WA; Van Harmelen JH; Monroe JE; Greenhalgh T; Williamson C; Williamson AL
AIDS Res Hum Retroviruses; 2008 Feb; 24(2):207-17. PubMed ID: 18240963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
